Emgality provided a ≥50% reduction from baseline in weekly cluster headache attacks in most patients at Week 31
- 71.4% of patients on Emgality 300 mg (N=49) experienced a ≥50% response from baseline vs 52.6% of patients on placebo (N=57) (p=0.046)
Emgality reduced the number of weekly cluster headache attacks by an average of 8.7 vs. 5.2 with placebo over Weeks 1 to 3 (baseline 17.8 vs 17.3) (p=0.036)1
Emgality is indicated for the treatment of episodic cluster headache in adults.
Emgality is the first and only calcitonin gene-related peptide (CGRP) antibody FDA approved for the treatment of episodic cluster headache in adults1,2
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085.